
Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
In the November 2026 episode of PharmTech’s Ask the Expert video series, Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel answer a question from a company whose contract development and manufacturing organization (CDMO) received an FDA warning letter. The sponsor company has a robust supplier selection process that includes audits and frequent communication. Even so, it was surprised by how deep the FDA’s observations went. How could the warning letter been prevented?
Related to this article








